Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
207 hedge funds and large institutions have $1.6B invested in Avadel Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 44 increasing their positions, 72 reducing their positions, and 49 closing their positions.
121% more call options, than puts
Call options by funds: $100M | Put options by funds: $45.3M
41% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 49
31% more capital invested
Capital invested by funds: $1.22B → $1.6B (+$376M)
10% more funds holding
Funds holding: 188 → 207 (+19)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
6.83% less ownership
Funds ownership: 82.36% → 75.53% (-6.8%)
39% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$87.7M |
| 2 |
TAL
TIG Advisors LLC
New York
|
+$74.9M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$57.1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$54.8M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$39.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$109M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$101M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
-$82M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$61.1M |
| 5 |
Morgan Stanley
New York
|
-$33.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIC
251
Salem Investment Counselors
Winston Salem,
North Carolina
| – | -$6.87K | -450 | Closed |
|
252
Daiwa Securities Group
Tokyo,
Japan
| – | -$5K | -332 | Closed |
|
|
ASN
253
Advisory Services Network
Atlanta,
Georgia
| – | -$4.05K | -265 | Closed |
|
254
Optiver Holding
Amsterdam,
Netherlands
| – | -$3.45K | -226 | Closed |
|
|
NA
255
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1.85K | -121 | Closed |
|
|
CA
256
Clearstead Advisors
Cleveland,
Ohio
| – | -$230 | -15 | Closed |
|
AVDL Hedge Fund Activity: Q4 2025 in Review
207 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2025, worth a combined $1.6B — up 31% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new AVDL positions and 49 closed out — a net gain of 20 holders — while 44 added to existing stakes and 72 trimmed.
The largest buyer was Weiss Asset Management, opening a new position worth an estimated $87.7M. The largest seller was Janus Henderson Group, cutting an estimated $109M.
- 207 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2025, up from 188 in Q3 2025.
- Funds reported $1.6B of Avadel Pharmaceuticals stock for Q4 2025, up 31% quarter-over-quarter.
- 69 funds opened new Avadel Pharmaceuticals positions in Q4 2025 and 49 closed out, a net change of +20 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2025 was Weiss Asset Management, an estimated $87.7M added.
- The largest Avadel Pharmaceuticals seller in Q4 2025 was Janus Henderson Group, an estimated $109M sold.
Based on aggregated 13F filings for Q4 2025.